Details

Autor(en) / Beteiligte

• TROUP, Sandra
• NJUE, Catherine
• KLIEWER, Erich V
• PARISIEN, Michelle
• ROSKELLEY, Cal
• CHAKRAVARTI, Shukti
• ROUGHLEY, Peter J
• MURPHY, Leigh C
• WATSON, Peter H

Titel

Reduced Expression of the Small Leucine-rich Proteoglycans, Lumican, and Decorin Is Associated with Poor Outcome in Node-negative Invasive Breast Cancer

Ist Teil von

• Clinical cancer research, 2003-01, Vol.9 (1), p.207-214

Ort / Verlag

Philadelphia, PA: American Association for Cancer Research

Erscheinungsjahr

2003

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose: To examine the prognostic significance of lumican and decorin, two abundant small leucine-rich proteoglycans in breast tissue stroma. Experimental design: Lumican and decorin expression was examined in a cohort of 140 invasive breast carcinomas by Western blot analysis. All cases were axillary lymph node-negative and treated by adjuvant endocrine therapy. Results: Lumican and decorin expression was highly correlated ( r = 0.45, P < 0.0001), but although low levels of lumican were associated with large tumor size ( P = 0.0496), negative estrogen receptor ( P = 0.0024) and progesterone receptor status ( P = 0.0116), and increased host inflammatory response ( P = 0.0077), low decorin levels were associated only with large tumor size ( P = 0.0496). However, using univariate analysis, low levels of lumican and decorin were both associated with a shorter time to progression ( P = 0.0013 and 0.0262) and poorer survival ( P = 0.001 and 0.0076). In multivariate analysis using the Cox regression model, low decorin was also shown to be an independent predictive factor for recurrence (hazard ratio 2.25: 95% confidence interval 1–5, P = 0.047) and survival (hazard ratio 3.39: 95% confidence interval 1.2–9.6, P = 0.021). Conclusion s : These results suggest that low levels of small leucine-rich proteoglycans in breast tumors may be associated with a worse prognosis in lymph node-negative invasive breast carcinomas and warrant further study with larger patient cohorts.